Ampio's Vyrix withdraws IPO

The Vyrix Pharmaceutical Inc. subsidiary of Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) withdrew its proposed IPO on NYSE MKT, citing market conditions. In April, Vyrix filed to raise up to $28.8 million. Aegis Capital and Fordham were underwriters.

In December 2013, Ampio carved out its sexual dysfunction business into Vyrix. The subsidiary's lead product is Zertane tramadol, an oral fast-dissolving tablet formulation of tramadol hydrochloride in development to treat premature ejaculation. ...